Member Info for Chris0123

Well, Hemogenyx has clawed it's way to the cusp of clinical trials and is now about to cross the "valley of death", as it is known in biotech, between pre-clinical and clinical stage. We are about to summit (this peak at least) albeit low on oxygen. Prove efficacy and there will be a few well-healed sherpa's willing to help us on our climb. GLA

Early December's Biodefense presentation of CBR by invite remember should be extremely interesting. Note that Prevail representatives were at the first presentation of CBR and were vocally pushing for partners to join them at the end of VS's presentation. They see it's value it seems and just maybe their 6p reflects their belief in CAR T and CBR delivering significantly north of their 6p. They are there to make money in life sciences to help life sciences. GLA

Sums it up nicely HFH

Fortunately it was only the share price which flatlined today. An injection should cure it. We also have CPR (sorry CBR) as a back-up!!!

Https://search.app/?link=https%3A%2F%2Fwww.biospace.com%2Fcar-t-cell-therapy-market-is-rising-rapidly-at-cagr-29-8-percent-by-2032%23%3A~%3Atext%3DNorth%2520America%2520CAR%2520T%252Dcell%2C29.9%2525%2520from%25202023%2520to%25202032.&utm_campaign=aga&utm_source=agsadl2%2Csh%2Fx%2Fgs%2Fm2%2F4

Haha rightly enough, them too tsbs !!

Apprehension; fear; anxiety; dread; uneasiness; sweating; restlessness; tense; poor sleep; nervousness; uncertainty; turmoil; irritable; lack of concentration; nausea; sweating; trembling; shaking; palpitations; panic attacks; family worries financial & emotional - NOT US, the trial patient - we are simply investors !! Make it work Vlad.

Just the experience we need IG.

An extract from the link Glass half drunk attached:

"Muchof this support ($80m) is directed to underwriting clinical trials that will accelerate treatments to the bedside".

Underwriting I guess being loans or investments. Either way, if supporting Hemo out of this or other funds means we have a financial interest coming from a renowned Cancer treatment centre who will then have a primary interest in ensuring Hemo CAR T is progressed. Also, again in March 25 when CAR T trials for kids commences. As stated MD approached Hemo. GLA

I see the quality of the contributions has not improved, with a few exceptions of course. C'mon guys you can better than this!

Err did not know that - same issues different strategy!!

Ssccss - I took the opportunity to review some of your posts from other companies - Synergia is one example and here is what you said on one occasion:

"Yes, the new wells should boost the sp significantly. However, Syn is currently undervalued even for the work over wells and Selan carry. I think this is mainly due to uncertainty around timelines and funding.

So hopefully, Roland can give us some confidence around workover timelines, when we can expect some income and how Syn will fund itself until the new wells come online mid 2025."

Substitute in Hemo name and activity and you get this:

Yes, the CLINICAL TRIALS should boost the sp significantly. However, HEMO is currently undervalued even for the OPPORUNITIES CAR T CBR carry. I think this is mainly due to uncertainty around timelines and funding.

So hopefully, Dr Sandler can give us some confidence around DEVELOPMENT timelines, when we can expect some income and how HEMO will fund itself until the new CLINICAL TRIALS come online mid 2025.

I am guessing your agenda for HEMO is entirely different to SYN much like your attitude and shorting Hemo to death.

Thanks for clarifying Haywain. My frustration is that links are posted for the reason I stated and it's a bit to easy to do to be honest. There at least needs to be some attempt at comment from the poster (I am sure his intentions were honest) to show some kind of will to put it into context with what Hemo or doing, or, alternatively, put it out there for clarification. Everyone ignore the link.

It's funny how the reference to leak has gained such momentum. I did not hear anyone talking about there being a "leak" before today's post. Now suddenly the "leak" is the problem. For a "leak" to have impact it must become known to people and to which they would then react to impact the subject-matter. Noone is even offering where the "leak" came from, not even Peter Redmond, reason, it's "unattributed" - Hemogenyx have multiple partners, could have come from any of them and be an internal and ineffective matter. A true leak of any real impact would have been addressed with an RNS I would wager. So, let's just accept that trials are later this year and this has caused jittery shareholders and shorters galore. Peter Redmond has allegedly clarified the reason for dealys in his reference to "committees" and I don't see the naysayers accepting that the delay to trials now seems to be explained. Probably someone left a tap leanning and noone has owned up! GLA

Alak could you explain your reason for posting the link and share your thoughts on how this might or might not have relevance to what MD will be engaging in with Hemogenyx. In instances where there is no obvious broader statements within the article, it's just a link to something which has similar letters or words in it. Haywain where are you mate.

For those who so quickly jumped on the two words "unattributed leaks" reveal so much about about their strategy to scaremonger at every opportunity. Forget everything else in the very kindly shared communication.

Pumpky I think it is simply that VS is now dealing with MD a relatively new partner and he is beginning to realise that they have processes to go through and the wheels mover slowly - certainly for us we know. VS, having realised that, has had to temper his vocabulary - you simply cannot keep using "imminently" so he has left it wider "later this year", wider than even he would have liked. He wcertainly would not have used "later this year" if he was seeking to get a dilutive raise away, albeit a small one. Time will tell for us all.

Pumpky - if we accept that trials are "later this year" as you state, as we often look at semantics, here's one:-

When you are waiting for a train to arrive , you are "expecting" it to arrive - expecting suggests you have no control, you rely on the driver, a third party to enable it to arrive.

"Expected" as used by VS suggests that the start of trials is outside of his control, he is waiting on the actions of others to start trials. It suggests someone else is involved and there is no reliance on him (eg to go and get funding, nor is it conditional on him...he is waiting on others to provide the means to make trials happen - trials therefore are not relying on a placing because he woould have control of that. This certainly suggests that trials WILL start. Some are doubting that, but the starting date is outside his direct control. If he is "expecting" the trials to start then he is both "expecting" a starting date and "expecting" funding to be in place facilitating their commencement. Again, If he was doing a dilutive raise he would not be "expecting" he would know. This leads me to believe that MD will fund and VS trials are "expected later this year" presumably because this needs to be worked through MD protocols & committees before sign off and over which he has no control because, in this analogy, he is not the train driver. GLA

From what knowledge I have gleaned from manufacturing companies, the weekend shift invariably leave a right old mess for those coming in on a Monday morning and sadly it can be evidenced here too, with the exception of one or two. Prevail are simply not going to commit to paediatric trials in March if they had concerns over Hemogenyx getting to first base, first set of trials. So, weekenders, calm jourselves down before this weekend. GLA

Sccss I see you are on the negativity roster along with Stu and JohnHenry. Adds a new meaning to "short" staffed.

When someone is really invested in a share you get to see some light and shade within their posts - yes, they are at times emotional, even worried about their choice of investment but mostly genuine and looking for educated support from like people.

No light and shade from those employed to derail a stock, every angle or view taken is cynical at it's worst and certainly show no detectable evidence of having genuine concerns for investors or the progress of a product.

I hope you are well-paid financially as there will be no benefit in kind. GL to the caring believers in this stock.